Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Open-label Study on Pharmacokinetics, Safety, Efficacy, and Immunogenicity of Cipterbin Combined With Vinorelbine Injection Every Week or Every Three Weeks in the Treatment of Patients With HER2-positive Metastatic Breast Cancer

NCT05131841 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT05131841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05131841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Open-label Study on Pharmacokinetics, Safety, Efficacy, and Immunogenicity of Cipterbin Combined With Vinorelbine Injection Every Week or Every Three Weeks in the Treatment of Patients With HER2-positive Metastatic Breast Cancer
Lead sponsor
Zhejiang Cancer Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
January 4, 2021
Completion date
December 30, 2022
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer